A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression
Latest Information Update: 23 Sep 2022
At a glance
- Drugs Busulfan (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Autologous stem cell therapy
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms BuMelMCRN001
- 20 Sep 2022 Status changed from active, no longer recruiting to completed.
- 01 Jul 2021 Results of a study assessing performance of EasyM (MS-based assay for M-protein monitoring) using serum samples of 26 MM patients enrolled in MCRN-001 study published in the Clinical Cancer Research
- 05 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2022.